Erratum to "P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients". [Pathol. Res. Pract. 203 (2007) 1-7] (DOI:10.1016/j.prp.2006.09.004);P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients

Pathology Research and Practice

Volumn 203, Issue 1, 2007, Pages 1-7

  Tanaka, Paula Yurie ^a,b   Calore, Edenilson Eduardo ^a,b  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HIV; Lymphomas; P glycoprotein

Indexed keywords

ANTIRETROVIRUS AGENT; CD15 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD45RO ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TRANSPORT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 33846306404     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.04.001     Document Type: Erratum

References (34)

1. Appelbaum F.R., Sullivan K.M., Buckner C.D., Clift R.A., Deeg H.J., Fefer A., Hill R., Mortimer J., Neiman P.E., Sanders J.E., Singer J., Stewart P., Storb R., and Thomas E.D. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J. Clin. Oncol. 5 (1987) 1340-1347
2. Arzoo K.K., Xiangdong B., Espina B.M., Seneviratne L., Nathwani B., and Levine A.M. T-cell lymphoma in HIV infected patients. J. Acquir. Immune Defic. Syndr. 36 (2004) 1020-1027
3. Biggar R.J., Engels E.A., Frish M., Goedert J.J., and James J. Risk of T-cell lymphomas in persons with AIDS. J. Acquir. Immune Defic. Syndr. 26 (2001) 371-376
4. Bower M., Gazzard B., Mandalia S., Newsom-Davis T., Thirlwell C., Dhillon T., Young A.M., Powles T., Gaya A., Nelson M., and Stebbing J. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann. Intern. Med. 143 (2005) 265-273
5. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-Lopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N.L., Armitage J.O., Carter W., Hoppe R., and Canellos G.P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI Sponsored International Working Group,. J. Clin. Oncol. 17 (1999) 1244-1253
6. Croop J.M. P-glycoprotein structure and evolutionary homologies. Cytotechnology 12 (1993) 1-32
7. DioDato G., and Sharon F.J. Interaction of combination of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter. Biochem. Pharmacol. 53 (1997) 1789-1797
8. Dupuis M.L., Tombesi M., and Cianfriglia M. Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitors (PI's) and cytotoxic drugs. Ann. Ist. Super. Sanita. 38 (2002) 387-392
9. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., and Miller T.P. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl. J. Med. 328 (1993) 1002-1006
10. A.T. Fojo, K. Ueda, D.J. Salmón, D.G. Poplack, M.M. Gottesman, I. Pastan, Expression of a multidrug-resistance gene in human tumors and tissues, Proc. Acad. Sci. USA 84, 265-269.
11. Goedert J.J. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin. Oncol. 27 (2000) 390-401
12. Hegewish-Becker S., and Hossfeld D.K. The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann. Hematol. 72 (1996) 105-117
13. Hsu S.M., Raine L., and Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am. J. Clin. Pathol. 75 (1981) 816-820
14. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
15. Levine A.M., Sullivan-Halley J., Pike M.C., Rarick M.U., Loureiro C., Bernstein-Singer M., Willson E., Brynes R., Parker J., and Rasheed S. HIV related lymphoma: prognostic factors predictive of survival. Cancer 68 (1991) 2466-2472
16. Levine A.M. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin. Oncol. 27 (2000) 442-453
17. Levine A.M., Tulpule A., Espina B., Sherrod A., Boswell W.D., Lieberman R.D., Nathwani B.N., and Welles L. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J. Clin. Oncol. 22 (2004) 2662-2670
18. Little R.F., Pittaluga S., Grant N., Steinberg S.M., Kavlick M.F., Mitsuya H., Franchini G., Gutierrez M., Raffeld M., Jaffe E.S., Shearer G., Yarchoan R., and Wilson W.H. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101 (2003) 4653-4659
19. Liu Q., Oshima K., and Kikuchi M. High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma. Histopathology 38 (2001) 209-216
20. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., and Salmon S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J. Clin. Oncol. 9 (1991) 17-24
21. Mounier N., Spina M., Gabarre J., Raphael M., Rizzardini G., Golfier J.-B., Vaccher E., Carbone A., Coiffier B., Chichino G., Bosly A., Tirelli U., and Gisselbrecht C. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107 (2006) 3832-3840
22. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., and Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 6 (1982) 649-655
23. Pileri S.A., Sabattini E., Falini B., Tazzari P.L., Gherlinzoni F., Michieli M.G., Damiani D., Zucchini L., Gobbi M., and Tsuruo T. Immunohistochemical detection of the multidrug transport protein P170 in humam normal tissues and malignant lymphomas. Histopathology 2 (1991) 131-140
24. Ratner L., Lee J., Tang S., Redden D., Hamzeh F., Herndier B., Scadden D., Kaplan L., Ambinder R., Levine A., Harrington W., Grochow L., Flexner C., Tan B., and Straus D. AIDS Malignancy Consortium, chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J. Clin. Oncol. 19 (2001) 2171-2178
25. Sandor V., Wilson W., Fojo T., and Bates S. The role of MDR-1 in refractory lymphoma. Leuk. Lymphoma 28 (1997) 23-31
26. Schoenlein P.V. Molecular cytogenetics of multiple drug resistance. Cytotechnology 12 (1993) 63-89
27. Sonneveld P. Multidrug resistance in hematological malignancies. J. Intern. Med. 247 (2000) 521-534
28. Sparano J.A., Lee S., Chen M., Nazeer T., Einzig A., Ambinder R.F., Henry D.H., Manalo J., Li T., and Von Roenn J.H. Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide (CDE) in HIV associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J. Clin. Oncol. 22 (2004) 1491-1500
29. Straus D.J.H., Huang J., Testa M.A., Levine A.M., and Kaplan L.D. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low dose versus standard dose m-BACOD plus granulocyte-macrophage stimulating factor. J. Clin. Oncol. 16 (1998) 3601-3606
30. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl. J. Med. 329 (1993) 987-994
31. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Acad. Sci. USA 84 (1987) 7735-7738
32. Tulpule A., Sherrod A., Dharmapala D., Young L.L., Espina B.M., Sanchez M.N., Gill P.S., and Levine A.M. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk. Res. 2 (2002) 121-127
33. Vaccher E., Tirelli U., Spina M., Talamini R., Errante D., Simonelli C., and Carbone A. Age and serum LDH level are independent prognostic factors in HIV related non-Hodgkin's lymphoma: a single institution study of 96 patients. J. Clin. Oncol. 14 (1996) 2217-2223
34. van der Heyden S., Gheuens E., De Bruijn E., Van Oosterom A., and Maes R. P-glycoprotein: clinical significance and methods of analysis. Crit. Rev. Clin. Lab. Sci. 32 (1995) 221-264